Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-09
2011-08-09
Kosar, Andrew D (Department: 1619)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S401000
Reexamination Certificate
active
07994153
ABSTRACT:
The present invention provides a composition that can effectively improve melasma and a composition that can effectively reduce skin dullness.The composition for improving melasma comprises a purine nucleic acid-related substance and a pharmaceutically or cosmetically acceptable carrier, and exhibits an excellent melasma improving effect due to the action of the purine nucleic acid-related substance contained. The composition for reducing skin dullness comprises a purine nucleic acid-related substance and a pharmaceutically or cosmetically acceptable carrier, and exhibits an excellent effect of reducing skin dullness due to the action of the purine nucleic acid-related substance contained.
REFERENCES:
patent: 4279262 (1981-07-01), Horin et al.
patent: 4294852 (1981-10-01), Wildnauer et al.
patent: 4569839 (1986-02-01), Grollier et al.
patent: 4946832 (1990-08-01), Goode et al.
patent: 5160739 (1992-11-01), Kanga
patent: 5466719 (1995-11-01), Jakobson et al.
patent: 5618522 (1997-04-01), Kaleta et al.
patent: 5637293 (1997-06-01), Honda
patent: 5688831 (1997-11-01), El-Nokaly et al.
patent: 5811112 (1998-09-01), Chandar et al.
patent: 5932608 (1999-08-01), Nguyen et al.
patent: 5955109 (1999-09-01), Won et al.
patent: 6060041 (2000-05-01), Candau et al.
patent: 6074652 (2000-06-01), Ishiwatari et al.
patent: 6316012 (2001-11-01), N'Guyen et al.
patent: 6376481 (2002-04-01), Bruce et al.
patent: 6465440 (2002-10-01), von Borstel et al.
patent: 6946436 (2005-09-01), Wakamatsu et al.
patent: 2001/0007677 (2001-07-01), Nagatani et al.
patent: 2001/0018568 (2001-08-01), Iga et al.
patent: 2001/0047039 (2001-11-01), McManus et al.
patent: 2002/0006383 (2002-01-01), Anderson et al.
patent: 2002/0006425 (2002-01-01), Takaoka et al.
patent: 2002/0034525 (2002-03-01), Sakai et al.
patent: 2004/0029761 (2004-02-01), Wakamatsu et al.
patent: 2004/0116373 (2004-06-01), Okuda et al.
patent: 1 498 101 (2005-01-01), None
patent: 47-26687 (1972-07-01), None
patent: 5-331142 (1993-12-01), None
patent: 7-277939 (1995-10-01), None
patent: 8-99860 (1996-04-01), None
patent: 8-119825 (1996-05-01), None
patent: 9-143063 (1997-06-01), None
patent: 9-183718 (1997-07-01), None
patent: 9-249550 (1997-09-01), None
patent: 9-291011 (1997-11-01), None
patent: 10-7541 (1998-01-01), None
patent: 10-95704 (1998-04-01), None
patent: 10-114670 (1998-05-01), None
patent: 10-182411 (1998-07-01), None
patent: 10-182412 (1998-07-01), None
patent: 11269049 (1999-10-01), None
patent: 2000-212025 (2000-08-01), None
patent: 2000-212056 (2000-08-01), None
patent: 2000-256188 (2000-09-01), None
patent: 2002-370986 (2002-12-01), None
patent: WO 98/15276 (1998-04-01), None
patent: WO 99/55302 (1999-11-01), None
patent: WO 00/24365 (2000-05-01), None
patent: WO 02/41853 (2002-05-01), None
patent: WO 02/083087 (2002-10-01), None
Melasma. MedlinePlus Medical Dictionary. http://ww2.merriam-webster.com/cgi-bin/mwmednIm. Accessed Feb. 6, 2009.
Mottled. Webster's Third New International Dictionary.
Mottling. Stedman's 27thEdition. http://www.thomsonhc.com/pdrel/librarian/PFDefaultActionld/pdrcommon.Stedmans. Accessed Feb. 5, 2009.
Karlshamns. International Magazine. Apr. 2002.
Supplementary European Search Report dated Oct. 20, 2009, in Application No. 03728092.2.
Kitano Y., “Effects of dibutyryl adenosine 3′,5′-cyclic monophosphate on human melanocytes in vitro,”Acta Dermatovener, 56:223-28 (1976).
McGuire J., “Melanocyte function: Influence of cyclic adenosine monophosphate,”Clin. Pharmacol. and Therap., 16:954-58 (1974).
Piamphongsant T., “Treatment of melasma: a review with personal experience,”Inter. J. Dermatol., 37:897-903 (1998).
Wikswo M.A., “Action of cyclic AMP on pigment donation between mammalian melanocytes and keratinocytes,”Yale J. Biol. and Med., 46:592-601 (1973).
Furuta Yasuo
Harano Fumiki
Kamimura Junko
Kawabata Shigekatsu
Kawamura Mitsuaki
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Kosar Andrew D
Mattison Lori K
Otsuka Pharmaceutical Co. Ltd.
LandOfFree
Chloasma amelioration composition and dullness amelioration... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chloasma amelioration composition and dullness amelioration..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chloasma amelioration composition and dullness amelioration... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2651650